Novo Nordisk B A/S

NOVO-B 
(NasdaqOMXC) 
 

To view this page ensure that Adobe Flash Player version 10.0.0 or greater is installed.

dkk 294.00 <%= Resources.Global.txtUp %>
Updated 23/06/2017
Change % 0.62% Stock price increasing
Change 1.80 Stock price increasing
Volume 3,182,920
High DKK 294.80
Low DKK 291.30
Open DKK 292.00
ISIN DK0060534915
Prev close DKK 292.20
# of shares 1,962.56M
Market cap 576,994M DKK
Intraday

Market closed
Novo Nordisk B A/S
Market is closed, opens at 08:00
 
Price development Latest 1 week 1 month 3 months 6 months 1 year
 
  294.00 3.2% Stock price increasing 6.1% Stock price increasing 26.9% Stock price increasing 15.3% Stock price increasing -14.8% Stock price decreasing
Key Figures (m DKK)
Turnover
EBIT
Net Profit
Equity
Balance
2016
0
48,432
37,925
45,269
97,539
2015
107,927
49,444
34,860
46,969
91,799
2014
88,806
34,492
26,481
40,294
77,062
2013
83,572
31,493
25,184
42,569
70,337
2012
78,026
28,142
21,432
40,632
65,669
2011
66,346
22,374
17,097
37,448
64,698
2010
60,776
18,891
14,403
36,965
61,402
2009
51,078
14,933
10,768
35,734
54,742
2008
45,666
12,405
9,666
33,058
0
2007
41,889
8,955
8,535
32,223
0
Powered by TradingView

News about Novo Nordisk B A/S

  • English
  • Regulatory news

Related

Latest 1 week 1 month 3 months 6 months 1 year
YTD
 
Indices Open
 
OMX Copenhagen 20 CAP 1,168.23 0.4% Stock price increasing 1.8% Stock price increasing 9.0% Stock price increasing 15.6% Stock price increasing 19.0% Stock price increasing 14.6% Stock price increasing

Company profile

Headquartered in Denmark, Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Novo Nordisk employs approximately 40,000 employees in 75 countries, and markets its products in more than 180 countries.

Targets for: Novo Nordisk B A/S

Ritzau Finans
 
Analyst
Target
Date
Novo/Exane: Hæver kursmålet til 285 kr. fra 270 kr.
BNP Paribas
285 op
09/05/17
Novo/Exane: Kursmålet skæres til 270 kr.
BNP Paribas
270
24/03/17
Novo/Exane: Kursmålet skæres til 270 kr.
BNP Paribas
270
24/03/17
Novo/Piper Jaffray: Sænker kursmål til 255 kr. fra 285 kr. - GENT
Piper Jaffray
255 ned
08/02/17
Novo/Piper Jaffray: Sænker kursmål til 255 kr. fra 285 kr.
Piper Jaffray
255 ned
08/02/17
Novo/Jefferies: Sænker kursmål til 230 kr. fra 285 kr.
Jefferies
230 ned
03/11/16
Novo/Piper Jaffray: Kursmål sænkes til 285 kr. fra 320 kr.
Piper Jaffray
285
28/10/16
Novo/Bernstein: Sænker kursmål til 275 fra 310
Bernstein
275 ned
28/10/16
Novo/Bernstein: Sænker kursmål til 275 fra 310
Bernstein
275 ned
28/10/16
Novo/Credit Suisse: Kursmål sænkes med 75 kr. til 305 kr. - NY
Credit Suisse
305
17/10/16

Copyright Euroinvestor A/S 2017   Disclaimer and Terms of Use
Quote information is delivered by Interactive Data.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
24 June 2017 06:11:26
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20170623.1 - EUROWEB4 - 2017-06-24 07:11:26 - 2017-06-24 06:11:26 - 1000 - Website: OKAY